Table 1.
Clinical characteristics of study populations.
| SDBwAH | SDBsAH | p value† | |
|---|---|---|---|
| Case number | 26 | 9 | |
| Age (year) | 6.7 ± 2.1 | 7.4 ± 2.4 | ns |
| Male: Female | 20: 6 | 8: 1 | ns |
| BMI | 17.6 ± 4.9 | 17.5 ± 2.6 | ns |
| Atopy, n (%) | 13 (50.0) | 4 (44.4) | ns |
| PCV 7, n (%) | 5 (19.2) | 0 (0) | ns |
| PCV 13, n (%) | 14 (53.8) | 7 (77.8) | ns |
| OSA-18 | 68.0 ± 18.3 | 66.1 ± 17.8 | ns |
| WBC (1000/dL) | 8.3 ± 2.1 | 8.9 ± 2.1 | ns |
| Eosinophil (%) | 4.6 ± 3.8 | 3.7 ± 3.5 | ns |
| Total IgE | 377.3 ± 716.7 | 242.8 ± 184.2 | ns |
| A:N ratio (%) | 80.5 ± 7.9 | 46.6 ± 1.9 | <0.001** |
Data was represented as the mean ± standard deviation.
†Categorical variables were compared using the Chi-squared test or Fisher’s exact test, as appropriate, and continuous variables were analyzed by the Mann–Whitney U test between the two groups.
**p < 0.01.
SDBwAH, sleep-disordered breathing with adenoid hypertrophy; SDBsAH, sleep-disordered breathing without adenoid hypertrophy; BMI, body mass index; PCV, pneumococcal conjugate vaccine; OSA-18, Obstructive Sleep Apnea-18 questionnaire; A:N ratio, adenoid:nasopharynx ratio; ns: not significant.